In Vivo

Show me the money

Show me the money

Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues.

著者：Anil Shrivastava, David Bellaire and Ashish Singh

  • min read

記事

Show me the money
en

Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues.

Download the Full Report (pdf)
Tags

クライアント支援事例

A Medical Imaging Company’s CX Overhaul Boosts Customer Satisfaction and Revenue

ケーススタディを見る

戦略 A healthcare payer sets its own long-term health strategy

ケーススタディを見る

組織 A Regional Operating Model Lifts European Sales for a Medical Device Maker

ケーススタディを見る

お気軽にご連絡下さい

私達は、グローバルに活躍する経営者が抱える最重要経営課題に対して、厳しい競争環境の中でも成長し続け、「結果」を出すために支援しています。

お問い合わせ

How can we help you?

全てのオフィス